Sermorelin

—

evidence score

gh secretagogue

Prescription Only

GHRH 1-29GRF 1-29Geref+1 more

Sermorelin is a synthetic analog of the first 29 amino acids of growth hormone releasing hormone (GHRH 1-29). Unlike HGH, it stimulates the pituitary to produce GH in a pulsatile, physiological manner rather than delivering exogenous GH. FDA-approved for pediatric GH deficiency diagnosis and treatment; widely prescribed off-label by anti-aging and longevity physicians. Advantages over exogenous HGH: preserves pituitary function, more physiological GH pulses, lower feedback suppression, significantly lower cost. Often combined with GHRP-2 or ipamorelin to maximize GH pulse amplitude via dual-axis stimulation.

Evidence

No score yet

Safety

Unknown safety profile

Clinical Status

No formal phase listed

Last Sync

Not synced yet

Last Reviewed

Not reviewed yet

Physician Notes

Excellent pairing with tirzepatide/semaglutide for muscle preservation during GLP-1-mediated weight loss. Broad dosing range (200-3000mcg) allows conservative titration.

FDA Status:Available via 503A compounding pharmacies.

Monitoring

IGF-1 q3mo
Fasting glucose/HbA1c

Contraindications

Active malignancy
Pregnancy

Velix Health

Want this prescribed by a board-certified physician?

Velix Health physicians review your labs, build evidence-based protocols, and monitor your progress. Every prescription is referenced.

Apply for Membership

Dosing

Typical

300 mcg

100 mcgRange500 mcg

Frequencydaily (bedtime)

Set height & weight in Settings to see your dose.

Pharmacology

Half-life~11-12 minutes (plasma)

OnsetGH elevation within 15-30 minutes of injection; body composition changes 3-6 months

DurationSingle dose GH pulse 1-2 hours; cumulative effects require months

Routes

subcutaneous_injection

Evidence Score

—

0 studies indexed

Scoring Factors

Volume(24%)—

Quality(24%)—

Sample Size(12%)—

Consistency(14%)—

Replication(8%)—

Recency(18%)—

Evidence Levels

AScore ≥75 with at least 1 meta-analysis and 3+ RCTs

BScore ≥50 with at least 1 RCT or meta-analysis

CScore ≥25 — observational or animal evidence only

DScore <25 — very limited or preclinical data

Plain-English Snapshot

Sermorelin is currently categorized as a gh secretagogue compound.

Evidence scoring has not been fully computed yet, so interpret this profile as preliminary.

Safety scoring is incomplete. Start conservatively and monitor carefully.

Core mechanism

GHRH receptor agonist in anterior pituitary somatotrophs; increases cAMP via Gs-coupled receptor; amplifies pulsatile GH release; preserves hypothalamic-pituitary axis

Practical Context

Strongest current signals

No indexed study summaries yet.